Welcome to our dedicated page for Xilio Therapeutics SEC filings (Ticker: XLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xilio Therapeutics, Inc. (Nasdaq: XLO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Xilio is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies, and its filings offer detailed information on clinical progress, collaborations, financings, governance and listing status.
Through this page, readers can review current reports on Form 8-K in which Xilio reports material events such as pipeline and business updates, clinical trial milestones, collaboration developments with partners like Gilead, Roche and AbbVie, financings and warrant exercises, cash runway estimates, Nasdaq listing matters and changes in board leadership. Filings also describe events such as the initiation of Phase 2 dosing for efarindodekin alfa (XTX301), late-breaking data for vilastobart in microsatellite stable metastatic colorectal cancer, and approvals of equity incentive plans and stock option repricings by stockholders.
Investors can also consult proxy statements on Schedule 14A to understand proposals submitted to stockholders, including equity plan approvals and adjournment proposals, as well as the mechanics of special meetings. Other periodic reports, such as Forms 10-Q and 10-K when available, provide additional context on research and development expenses, collaboration and license revenue, net loss and risk factors related to Xilio’s clinical-stage operations and Nasdaq listing compliance.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as updated financial guidance, listing notifications, and the implications of collaboration terms or option milestones. Users can quickly identify disclosures on topics like cash and cash equivalents, stockholders’ equity, minimum bid price grace periods, and the structure of development and commercialization options under Xilio’s license agreements. This makes it easier to interpret lengthy SEC documents and understand how Xilio’s masked immuno-oncology strategy is reflected in its regulatory reporting.
Xilio Therapeutics (XLO) reported an equity compensation update for its chief medical officer. Under the new 2025 Stock Incentive Plan, approved by stockholders on November 21, 2025, the officer received a stock option for 625,000 shares at an exercise price of $0.841 per share. These options vest in 36 equal monthly installments starting December 21, 2025, so the grant is earned gradually over three years.
The filing also records a one-time option repricing effective November 21, 2025. Several existing stock options with higher exercise prices, including grants for 44,210 and 106,000 shares, were modified so that the exercise price is reduced to $1.50 per share. If any repriced option is exercised before November 21, 2026, the original, higher exercise price still applies, while all other vesting and expiration terms remain unchanged.
Xilio Therapeutics (XLO) reported equity compensation changes for its President and CEO, who is also a director, in a Form 4. The filing shows a new stock option grant covering 2,075,000 shares of common stock at an exercise price of $0.841 per share under the 2025 Stock Incentive Plan, which was approved by stockholders on November 21, 2025. These options vest in 36 equal monthly installments over three years beginning on December 21, 2025, contingent on continued service.
The filing also details a one-time option repricing effective November 21, 2025, reducing the exercise price of several existing stock options to $1.50 per share. If any repriced option is exercised before November 21, 2026, the original higher exercise price must be paid, and all other vesting and expiration terms for those options remain unchanged.
Xilio Therapeutics reported that stockholders approved two key compensation proposals at a special meeting. They approved a one-time repricing of certain outstanding employee stock options and the new 2025 Stock Incentive Plan, which had been previously adopted by the board subject to stockholder approval.
The repricing lowers the exercise price of affected options to $1.50 per share. For example, options for 2,198,212 shares held by the President and CEO previously had a weighted-average exercise price of $5.76, 848,172 shares held by the CFO had a price of $4.67, and 225,210 shares held by the Chief Medical Officer had a price of $4.10. If these repriced options are exercised within 12 months of November 21, 2025, the original higher exercise price must be paid, except in cases of death, disability, or a change in control.
The repricing proposal received 31,600,793 votes for and 1,690,846 against. The 2025 Plan was also approved, with 30,542,811 votes for and 2,876,155 against.
Xilio Therapeutics (XLO) reported Q3 2025 results highlighted by a sharp rise in collaboration and license revenue to $19.1 million from $2.3 million a year ago, driven by revenue recognition from its AbbVie and Gilead agreements. The quarter included a $7.0 million cumulative catch-up tied to a $17.5 million Gilead development milestone achieved in Q3.
The company posted a net loss of $16.3 million, as a $15.4 million non-cash loss from remeasuring warrant liabilities offset improved operating performance. Year-to-date revenue reached $30.1 million, with operating expenses of $60.2 million. Cash and cash equivalents were $103.8 million at September 30, 2025, up from $55.3 million at year-end, aided by a June follow-on offering with initial gross proceeds of $50.0 million and an AbbVie equity purchase.
Deferred revenue totaled $69.3 million (AbbVie $35.3 million; Gilead $34.1 million) to be recognized as services progress. The company states that recurring losses and funding needs raise substantial doubt about its ability to continue as a going concern. If exercised in cash, Series B and C warrants from the June offering could deliver up to $100.0 million in additional gross proceeds by 2026.
Xilio Therapeutics (XLO) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025, along with other business highlights. The full details are in a press release furnished as Exhibit 99.1 and incorporated by reference.
The company specifies the information is furnished, not filed, and therefore not subject to liability under Section 18 of the Exchange Act, except as expressly incorporated by reference.
Xilio Therapeutics (XLO) furnished an Item 7.01 update, providing two press releases with new and updated clinical and preclinical data. The company highlighted Phase 2 results related to high plasma tumor mutational burden for vilastobart in combination with atezolizumab in microsatellite stable metastatic colorectal cancer.
Additional disclosures included portfolio updates: preclinical findings from its masked T cell engager platform and programs, updated Phase 1 data for efarindodekin alfa, and Phase 2 circulating tumor DNA data for vilastobart. These data were presented in poster sessions at the Society for Immunotherapy of Cancer 40th Annual Meeting. The information, including Exhibits 99.1 and 99.2, was furnished—not filed—under Regulation FD and is not subject to Section 18 liabilities nor incorporated by reference unless specifically stated.
Xilio Therapeutics (XLO) called a special meeting to seek stockholder approval for two compensation actions. Proposal 1 requests a one-time repricing of certain employee stock options granted before January 1, 2025. Repriced options would carry a new exercise price of $1.50 per share for executives and $1.00 for other employees, or the closing price on the repricing date if higher, with a 12‑month retention condition before the lower price applies.
Proposal 2 seeks approval of the 2025 Stock Incentive Plan reserving 32.0 million shares for employee stock options in four equal tranches tied to June 2025 warrant tranches. Contingent grants equal to 32.0 million options were approved at an exercise price of $0.841 per share, subject to stockholder approval. As of September 30, 2025, approximately 87% of employee options were underwater at a closing price of $0.843. Only stockholders of record at close on October 15, 2025, when 51,830,450 shares were outstanding, may vote. Proposal 3 allows adjournment if needed.
Xilio Therapeutics, Inc. is soliciting votes at a virtual special meeting on November 21, 2025 to approve three proposals: a one-time repricing of certain outstanding employee stock options, adoption of the 2025 Stock Incentive Plan, and an adjournment option to allow further solicitation if needed. Stockholders must vote by November 20, 2025 for proxies to be valid and can attend at www.virtualshareholdermeeting.com/XLO2025SM.
The company disclosed substantial dilution from issued warrants: 25.6 million prefunded warrants in 2024 and 266.7 million prefunded and common stock warrants in June 2025. As of September 30, 2025, approximately 87% of employee stock options were underwater; the company says this harms retention. Since its IPO, the share price fell from $16.00 on 12/31/2021 to about $0.8383 on 10/9/2025. The repricing would reprice eligible options granted before 1/1/2025, exclude non-employee directors/consultants, and include vesting/holding period conditions and potential reversion to original exercise price after 12 months in some cases.
Xilio Therapeutics, Inc. is moving its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the open of business on October 6, 2025, while continuing to trade under the symbol XLO. This change follows a prior notice from Nasdaq on April 8, 2025 that the company no longer met the $1.00 minimum bid price requirement for the Global Select tier. In connection with the transfer, Nasdaq granted Xilio an additional 180 calendar days, until March 30, 2026, for its stock to close at or above $1.00 for at least 10 consecutive business days to regain compliance. The company states that it is continuing to evaluate options to restore compliance with the minimum bid price rule.
Xilio Therapeutics disclosed that it has begun dosing patients in Phase 2 of an ongoing Phase 1/2 trial of efarindodekin alfa (XTX301), a tumor-activated IL-12 being tested as a monotherapy in certain advanced solid tumors. The company also reported achieving a $17.5 million development milestone under its license agreement with Gilead Sciences tied to this program and referenced updated data from the ongoing Phase 1 trial.
As of June 30, 2025, Xilio had $121.6 million in cash and cash equivalents. It now expects that this balance, together with the $17.5 million milestone, will fund operating and capital needs into the first quarter of 2027. Xilio expects to receive the milestone payment by the fourth quarter of 2025.